| An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients B Györffy, A Lanczky, AC Eklund, C Denkert, J Budczies, Q Li, Z Szallasi Breast cancer research and treatment 123, 725-731, 2010 | 2890 | 2010 |
| Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer C Denkert, S Loibl, A Noske, M Roller, BM Müller, M Komor, J Budczies, ... Journal of clinical oncology 28 (1), 105-113, 2010 | 1949 | 2010 |
| Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer B Győrffy, P Surowiak, J Budczies, A Lánczky PloS one 8 (12), e82241, 2013 | 1734 | 2013 |
| Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ... The lancet oncology 19 (1), 40-50, 2018 | 1721 | 2018 |
| Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization J Budczies, F Klauschen, BV Sinn, B Győrffy, WD Schmitt, ... PloS one 7 (12), e51862, 2012 | 1176 | 2012 |
| The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma … A Warth, T Muley, M Meister, A Stenzinger, M Thomas, P Schirmacher, ... Journal of clinical oncology 30 (13), 1438-1446, 2012 | 707 | 2012 |
| Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression M Hilvo, C Denkert, L Lehtinen, B Müller, S Brockmöller, ... Cancer research 71 (9), 3236-3245, 2011 | 564 | 2011 |
| Tumor mutational burden as a predictive biomarker in solid tumors D Sha, Z Jin, J Budczies, K Kluck, A Stenzinger, FA Sinicrope Cancer discovery 10 (12), 1808-1825, 2020 | 489 | 2020 |
| Mass spectrometry–based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors C Denkert, J Budczies, T Kind, W Weichert, P Tablack, J Sehouli, ... Cancer research 66 (22), 10795-10804, 2006 | 466 | 2006 |
| Metabolite profiling of human colon carcinoma–deregulation of TCA cycle and amino acid turnover C Denkert, J Budczies, W Weichert, G Wohlgemuth, M Scholz, T Kind, ... Molecular cancer 7, 1-15, 2008 | 390 | 2008 |
| Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial C Denkert, S Loibl, BM Müller, H Eidtmann, WD Schmitt, W Eiermann, ... Annals of oncology 24 (11), 2786-2793, 2013 | 285 | 2013 |
| The landscape of metastatic progression patterns across major human cancers J Budczies, M von Winterfeld, F Klauschen, M Bockmayr, JK Lennerz, ... Oncotarget 6 (1), 570, 2015 | 282 | 2015 |
| Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma S Darb-Esfahani, CA Kunze, H Kulbe, J Sehouli, S Wienert, J Lindner, ... Oncotarget 7 (2), 1486, 2016 | 275 | 2016 |
| Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group C Denkert, S Wienert, A Poterie, S Loibl, J Budczies, S Badve, ... Modern Pathology 29 (10), 1155-1164, 2016 | 268 | 2016 |
| Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of … BM Müller, L Jana, A Kasajima, A Lehmann, J Prinzler, J Budczies, ... BMC cancer 13, 1-8, 2013 | 263 | 2013 |
| Strategies for developing Ki67 as a useful biomarker in breast cancer C Denkert, J Budczies, G von Minckwitz, S Wienert, S Loibl, F Klauschen The Breast 24, S67-S72, 2015 | 213 | 2015 |
| Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells N Eckstein, K Servan, B Hildebrandt, A Pölitz, G Jonquières, ... Cancer research 69 (7), 2996-3003, 2009 | 212 | 2009 |
| A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer Z Mihály, M Kormos, A Lánczky, M Dank, J Budczies, MA Szász, B Győrffy Breast cancer research and treatment 140, 219-232, 2013 | 198 | 2013 |
| Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism J Budczies, SF Brockmöller, BM Müller, DK Barupal, C Richter-Ehrenstein, ... Journal of proteomics 94, 279-288, 2013 | 184 | 2013 |
| Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians M Allgäuer, J Budczies, P Christopoulos, V Endris, A Lier, E Rempel, ... Translational lung cancer research 7 (6), 703, 2018 | 175 | 2018 |
Carsten DenkertProfessor of Pathology, Philipps-University Marburg, Germany在 uni-marburg.de 的电子邮件经过验证
